Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epistem CEO: Indian TB deal first among many for Genedrive

This article was originally published in Clinica

Executive Summary

Epistem last week announced a partnership with biotech firm Xcelris Laboratories to evaluate the Genedrive system – the UK company's point-of-need molecular diagnostics platform – for the early detection of tuberculosis (TB) in India. However, this deal is just the tip of the iceberg. Having spent four to five years developing the technology, Epistem has dedicated the last six months to ramping up production of the handheld analysers and building up the assay processes to support other deals – similar to the one it has with Xcelris – which it has lined up for Genedrive, according to Epistem CEO Matthew Walls.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel